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Highlights 
• 
Leucine and threonine are essential amino acids for calves. 
• 
Calves received milk replacer supplemented or not with 3% leucine and 3% 
threonine. 
• 
Supplementation with Thr and Leu leads to higher citrate cycle activity and 
OXPHOS. 
• 
Supplementation with Leu and Thr increased antioxidant defenses. 
• 
Supplementation with Leu and Thr increases the muscle Phospho-S6/S6 ratio. 
Abstract 
In pre-weaning calves, both leucine and threonine play important roles in growth and 
muscle metabolism. In this study, metabolomics, proteomics and clinical chemistry 
were used to assess the effects of leucine and threonine supplementation added to 
milk replacer on 14 newborn Holstein male calves: 7 were fed a control diet (Ctrl) and 
7 were fed the Ctrl diet supplemented with 0.3% leucine and 0.3% threonine (LT) 
from 5.6 days of age to 53.6 days. At this time, blood and semitendinosus muscle 
biopsies were collected for analysis. Integrated metabolomics and proteomics showed 
that branched-chain amino acids (BCAA) degradation and mitochondrial oxidative 
metabolism (citrate cycle and respiratory chain) were the main activated pathways in 
muscle because of the supplementation. BCAA derivatives and metabolites related to 
lipid mobilization showed the major changes. The deleterious effects of activated 
oxidative phosphorylation were balanced by the upregulation of antioxidant proteins. 
An increase in protein synthesis was indicated by elevated aminoacyl-tRNA 
biosynthesis and increased S6 ribosomal protein phosphorylation in skeletal muscle. 
In conclusion, LT group showed greater BCAA availability and mitochondrial 
oxidative activity; as the muscle cells undergo greater aerobic metabolism, antioxidant 
defenses were activated to compensate for possible cell damage. Data are available 
via ProteomeXchange (PXD016098). 
Significance 
Leucine and threonine are essential amino acids for the pre-weaning calf, being of 
high importance for growth. In this study, we found that leucine and threonine 
supplementation of milk replacer to feed pre-weaning calves led to differences in the 
proteome, metabolome and clinical chemistry analytes in skeletal muscle and plasma, 
albeit no differences in productive performance were recorded. This study extends our 
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1. Introduction 
Amino acids (AA) are important for the growth of pre-weaning calves being pivotal 
for tissue development, endocrine, and immune function [1,2]. Leucine is an essential 
AA and one of the more studied branched-chain AA (BCAA) in several species due to 
its function in promoting protein synthesis through the mammalian target of 
rapamycin (mTOR) pathway in skeletal muscle [3,4]. Leucine also enhances energy 
homeostasis through increasing fatty acid oxidation and provides skeletal muscles 
with an increased flux of lipids to supply energy and intermediary substrates to 
support protein synthesis [5]. Leucine from dietary protein can bypass metabolism in 
the liver, which results in a rise of plasma leucine levels and the activation of leucine 
signaling in peripheral tissues in response to a meal [6] and, among these 
tissues/organs, the skeletal muscle is the main site for BCAA oxidation [7]. Threonine 
is another essential AA that is often considered limiting in milk replacers (MR) for 
calves [8]. It participates in the synthesis of several other important AA such as 
glycine and serine which are involved in the production of collagen and muscle tissue, 
it also plays a central regulatory role in the immune system and is a major component 
of intestinal mucins and plasma γ-globulins [1,9]. 
To understand the role of nutritional compounds at the molecular level [10] and to 
analyze the coordination of multiple systems including for instance the immune, 
digestive and endocrine, the identification of large sets of biological molecules is 
required. Accordingly, “multi-omics” approaches have gained popularity in animal 
science. The combination of proteomics and metabolomics in food and nutrition 
science, more recently named as “foodomics”, has been shown to be a more suitable 
approach compared to other “-omics” such as genomics or transcriptomics [10]. 
The objective of this work is to use a foodomics-based approach in calves' skeletal 
muscle and plasma in order to fully assess the effects of leucine and threonine 
supplementation in the milk replacer (MR) during the pre-weaning period, under the 
hypothesis that AA supplementation will modify the energy metabolism, especially in 
the muscle tissue. Furthermore, the activation of the mTOR pathway was studied in 
skeletal muscle by determining the phosphorylation of S6 ribosomal protein, a key 
event in protein synthesis. 
2. Materials and methods 
2.1. Animal housing and diet management 
Animal management followed the recommendations of the Animal Care Committee 
of Institut de Recerca i Tecnologia Agroalimentàries (IRTA) under the approval 
research protocol FUE-2017-00587321, authorization code 9733. 
Fourteen Holstein male calves (41.9 ± 0.67 kg of body weight (BW) at age of 
5.6 ± 0.67 days) were obtained from Granja Murucuc (Gurb, Barcelona, Spain) and 
housed individually at IRTA Torre Marimon (Caldes de Montbui, Barcelona, Spain) 
and fed a milk protein-based MR twice a day. The MR contained 24% crude protein 
(based in skimmed milk protein and whey protein concentrate) and 20.3% fat, on a 
DM basis. Calves were fed 4 L/day at 15% dry matter (DM) concentration from days 
1 to 7 of experiment. Then, MR volume was increased to 6 L/day from 8 to 49 days of 
age, and it was reduced to one single feeding of 3 L/day until animals were weaned. 
Calves were divided into control (Ctrl, n = 7) and Ctrl supplemented with 0.3% 
leucine and 0.3% threonine (LT, n = 7) groups according to the AA profile in the MR 
formula. Ingredient and chemical composition are shown in Supplementary material 
(Table S1). All AA were provided by Livzon Group (Fuxing Pharmaceutical, Ningxia, 
China). All animals had free access to water, and restricted access to a pelleted 
concentrate starter feed to minimize the impact of concentrate feeding on AA supply. 
The starter feeding program is shown in Supplementary material (Table S2). Chopped 
barley straw was offered ad libitum during the study. 
2.2. Sample collection 
At 53.6 ± 0.67 days of age and 81.8 ± 3.49 kg of BW, blood was obtained from the 
jugular vein, 4 h after the morning MR feeding. Plasma and serum were obtained by 
centrifugation at 1500g for 10 min. Plasma and serum were aliquoted and stored at 
−80 °C until further analysis. Biopsies were obtained from the semitendinosus muscle 
as previously described [11] and kept at −80 °C until further analysis. Prior to Omics 
assays, frozen muscle tissues were ground into a fine powder with mortar and pestle 
in liquid nitrogen and at least two 0.5 g aliquots were made and kept in a 15 mL 
polypropylene vial at −80 °C. 
2.3. Serum clinical chemistry and plasma AA 
Serum clinical chemistry analytes were determined with an Olympus AU400 analyzer 
(Olympus corp., Tokyo, Japan). Methods, reagents and intra-assay CV (%) were 
previously reported [12]. Plasma AA were determined by HPLC as described [11] 
with some modifications. Briefly, an Elite LaChrom (Hitachi, Tokyo, Japan) equipped 
with an UV detector (Hitachi L-24200, Tokyo, Japan) with a Novapak C18 column 
(300 mm × 3.9 mm) from Waters (Milford, MA, USA) were used. The flow rate was 
1.0 mL/min, and the column temperature was kept at 42 °C. The injection volume was 
10 μL and the detection wavelength was set at 254 nm. The solvent system consisted 
of two eluents: (A) 140 mM sodium acetate trihydrate, 12 mM TEA and 1 mg/L 
EDTA at pH 5.02 and (B) 60% acetonitrile/40% water. The Agilent software 
EZChrom Elite system V3.1.7 (Santa Clara, CA, USA) was used for system control 
and data acquisition. 
2.4. Proteomic analysis 
2.4.1. Protein extraction and quantification 
One aliquot of semitendinosus muscle fine powder in a 15 mL tube was sonicated in 
3 mL extraction buffer (137 mM NaCl, 50 mM HEPES, 2% SDS, 1% NP-40, 10% 
glycerol, 2 mM Na3VO4, 100 mM NaF and 1% protease inhibitor cocktail (Sigma), 
pH 7.4) at 40% amplitude following a sequence of 10-s on and 5-s off, three times on 
ice. The homogenate was centrifuged at 12,000g for 15 min at 4 °C and the 
supernatant (muscle extract) retrieved. Protein concentration was determined using the 
Bradford method. Samples were kept at −80 °C until analyses. 
2.4.2. Protein immunoblot for S6 and Phospho-S6 in muscle 
All antibodies were purchased from Cell Signaling Technology (Denvers, MA, USA). 
15 μg of muscle extract per sample were subjected to 12% SDS-PAGE and transferred 
to PVDF membranes. Total protein staining (TSP) by Ponceau S was performed for 
band intensity normalization on membrane after transfer. The membranes were then 
immunoblotted with primary antibodies (1:2000) against S6 ribosomal protein 
(#2217) and phospho-S6 ribosomal protein (#4858). The dilution for secondary 
antibodies were 1:5000 and 1:2000 for S6 and phospho-S6, respectively. Immunoblot 
bands were processed using Multi Gauge software (Fujifilm, Tokyo, Japan). Each 
sample was normalized by dividing the band density by its normalization factor. The 
latter was in turn calculated taking into account the mean TPS density of all gels and 
the mean TPS density of the gel where the sample was placed. Immunoblots were 
repeated three times with a random distribution of samples between gels. 
2.4.3. Sample preparation for high resolution LC-MS/MS 
Muscle samples were processed using Filter-Aided Sample Preparation (FASP) with 
some modifications [13]. Briefly, for each sample and internal standard (pooled 
sample), 35 μg of proteins were diluted in UA buffer (8 M urea in 0.1 M Tris/HCl, 
pH 8.5) to 200 μL. They were then added to a 10 kDa filter unit (Microcon YM-10, 
Merck Millipore, Burlington, MA, USA), centrifuged at 13,000g for 15 min at 20 °C 
and washed by adding 200 μL of UA buffer followed by centrifugation. Samples were 
alkylated with 100 μL iodoacetamide (0.05 M IAA in UA buffer) for 20 min in the 
dark at RT. Additional series of washes with 100 μL of UA buffer (twice) and 100 μl 
TEAB (0.1 M triethylammonium bicarbonate) (twice) with subsequent centrifugation 
were conducted. Overnight digestion at 37 °C was performed with 50 μL of 0.1 M 
TEAB containing 2% trypsin (v/v). Tryptic peptides were eluted by centrifugation at 
13,000 g for 10 min and washed with 50 μL of buffer (50% acetonitrile in 0.1 M 
TEAB, v/v). Collected flowthrough was dried and used for TMT labelling. Before 
labelling, pellets were dissolved in 50 μL of 0.1 M TEAB. 
Plasma-EDTA samples were prepared as described [14] with some modifications. 
Briefly, 35 μg of proteins per sample or internal standard were diluted with 100 μL 
0.1 M TEAB containing 1% SDS, reduced, alkylated and acetone precipitated 
overnight. Protein pellets were collected by centrifugation and dissolved in 50 μL 
TEAB containing 1 μg trypsin for overnight digestion at 37 °C. 
2.4.4. Tandem Mass Tag (TMT) labelling for muscle and plasma proteins 
TMTsixplex™ Isobaric Label Reagent Set (#90061) from Thermo Fisher Scientific 
(Waltham, MA, USA) was used for peptide labelling. All reagents were prepared as 
previously reported [14,15]. Briefly, for the labelling, 19 μL of reconstituted TMT 
reagent was added to each tryptic digested sample and incubated for 1 h at room 
temperature. Internal standard was labelled with the TMT m/z 126 while other tags 
were randomized. The reaction was quenched by adding 8 μL of 5% hydroxylamine to 
each sample and a 15 min incubation. For each sixplex, samples were combined at 
equal amounts, aliquoted, dried in a vacuum centrifuge and kept in −80 °C until 
further analysis. 
2.4.5. High resolution LC-MS/MS analyses and bioinformatics 
Mass spectrometric analysis was conducted on an Ultimate 3000 RSLCnano system 
(Dionex, Germering, Germany) and Q Exactive Plus mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany) as reported [14]. In short, after desalting on the 
trap column, TMT-labelled peptides were separated on the analytical column 
(PepMap™ RSLC C18, 50 cm × 75 μm) using a 120-min linear gradient of 5–45% 
mobile phase B (0.1% formic acid in 80% ACN) at the flow rate of 300 nL/min. 
Peptides were introduced into the mass spectrometer using a 10 μm-inner diameter 
SilicaTip emitter (New Objective, Woburn, MA, USA) in a nanospray Flex ion 
source. For DDA analysis, the Top-8 method was used. 
Proteome Discoverer (version 2.0, Thermo Fisher Scientific, Waltham, MA, USA) 
was used for peptide identification and relative quantification. SEQUEST algorithm 
database search against Bos taurus FASTA files (NCBI database, 7/12/2017, 46,105 
entries) was performed. Proteins with at least two unique peptides and 5% FDR were 
reported as validly identified. Furthermore, for reporter ion-based protein 
quantification, internal standards were used to compare the data between the TMT 
sixplexes. For bioinformatics, NCBI accession number (gi number) was converted to 
gene symbol by Biological Database Network (https://biodbnet-
abcc.ncifcrf.gov/db/db2db.php) and protein function was explored with PANTHER 
(http://pantherdb.org/). 
2.4.6. Validation 
PON1 esterase activity was measured in plasma-heparin samples by analyzing the 
hydrolysis of phenyl acetate (arylesterase activity, ARE), as previously described 
[16]. 
2.5. Metabolomic analysis 
2.5.1. Muscle and serum extractions 
The extraction of the aqueous metabolites from muscle powder was performed as 
described [11]. For serum, 300 μL of each sample were extracted by methanol protein 
precipitation method as described [17], with the exception that dried samples were 
resuspended in 600 μl of NMR buffer. 
2.5.2. Data acquisition, processing and analyses 
For muscle, data acquisition method and parameters, data processing protocols and 
analyses were as described previously [11]. For serum samples, 128 scans and 8 test 
scans were applied. All raw data have been deposited to the EMBL-EBI 
MetaboLights database (https://www.ebi.ac.uk/metabolights/MTBLS1045). 
2.5.3. Spectral profiling for chemometrics 
All 1r data from either biological sample collected from Bruker were uploaded to 
NMRProcFlow 1.2 Online spectral processing tool interface [18]. Spectra were 
calibrated referring to the ppm and some peaks were aligned. H2O peak was zeroed. 
For bin data, peaks were bucketed following previous knowledge of assignment. Peak 
intensities for each sample were normalized by its own weight for muscle, no 
normalization for serum, and centered-scaled for both. 
2.6. Statistics 
All statistical analyses were performed using R (version 3.5.2) under RStudio (version 
1.2.1335), “dplyr” [19], “reshape2” [20], “ggpubr” [21], “ggplot2” [22], “corrplot” 
[23], “nortest” [24] and “openxlsx” [25] packages were used for data manipulation, 
statistics and graphic processes. Performance and intake data were analyzed using a 
mixed-effects model accounting for the fixed effects of treatment, time of 
measurement, and their 2-way interaction, and the random effect of calf. Time entered 
the model as a repeated measure using an autoregressive covariance matrix. Initial 
BW was used as a covariate in the model. For statistical difference (univariate 
analyses) in the serum clinical chemistry, plasma AA and metabolomic results, a one-
way analysis of variance (ANOVA) was used and for western blot and proteomic 
data, a Wilcoxon test was used, p between 0.05 and 0.1 was inspected, while <0.05 
was considered significant. For MS-proteomics, fold change between two groups was 
calculated using the function of log2(Mean(LT)/Mean(Ctrl)). Absolute value of fold 
change ≥0.20 and p < .05 were considered significant. Additionally, some 
proteins/metabolites with p between 0.05 and 0.1 or/and with fold changes between 
0.10 and 0.20 showing significant correlations with representative metabolites, were 
also included in the analysis. 
For univariate analyses in metabolomics, significant chemical shifts from 
chemometrics were inspected to assist the identification. For multivariate analyses, 
principle component analyses (PCA) with loadings of both quantified and 
chemometric data were plotted. The correlation plot in metabolomic results was made 
and Pearson r was used as distance measurement. 
All concentrations are presented in form of mean ± SE. 
2.7. Proteomic-metabolomic interactive analyses 
For significant proteins and metabolites, their official gene symbols (proteins) and 
compound names (metabolites) were analyzed using Reactome (version 69 released 
on June 12, 2019) (https://reactome.org/) [26] and Joint Pathway Analysis provided 
by MetaboAnalyst. Human (Homo sapiens) was selected as species since Bos 
taurus was not available in both databases. The hypergeometric test, degree centrality 
and gene-metabolite pathways options were used for enrichment, topology and 
pathway analyses, respectively, in the MetaboAnalyst. For unannotated proteins, 
literature and Uniprot were referred. 
3. Results 
3.1. Performance results 
The mean average daily gain (ADG) was 0.89 kg/d and 0.96 kg/d in Ctrl and LT 
calves respectively. No significant differences between groups in ADG, BW or food 
intake were recorded. Complete results are shown in Supplementary material (Table 
S3). 
3.2. Blood clinical chemistry and AA profile 
Analytes with significant differences between groups are shown in Table 1. Decreased 
GPx, increased cholesterol and a tendency for an increase in triglycerides were 
observed in the LT group. There was an increase in plasma isoleucine and histidine, 
and a tendency for an increase in leucine concentrations. Complete results are shown 
in Supplementary material (Table S4). All blood biochemistry parameters were within 
the reference interval for this species [12]. 
3.3. Proteomics in skeletal muscle and plasma 
The differentially abundant proteins in muscle and plasma from both groups are 
shown in Table 2, Table 3, respectively, and the raw proteomic data are presented in 
Supplementary material (Table S5 for muscle and Table S6 for serum, respectively. 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE [27] partner repository with the dataset 
identifier PXD016098. 
In muscle, nine proteins were found with higher abundances (HADHA, PRDX1, 
SOD2, COX2, COX5, NDUFAB1, ACO2, SLC25A4 and VCP) and two with lower 
abundances (GYS1 and RTN2) in LT animals in comparison to Ctrl animals. For 
increased abundance proteins, GO analysis indicates a positive regulation of ATP 
biosynthetic process (GO:2001171) and the removal of superoxide radicals 
(GO:0019430) as the most relevant biological processes and the antioxidant activity 
(GO:0016209) as the first molecular function. Complete GO analysis is shown in 
Supplementary material (Table S7). 
In plasma, five proteins were found with higher abundance (APOA2, APOC3, CRP, 
F2 and PON1) in treated animals. The GO analysis for biological process showed that 
three of them (APOA2, APOC3 and PON1) are related to regulation of cholesterol 
transport (GO:0032374) and chylomicron assembly (APOA2 and APOC3) 
(GO:0034378). CRP and F2 are associated to the acute phase response (GO:0006953). 
The GO analysis for molecular function showed three proteins related to lipoprotein 
receptor binding (APOA2, APOC3 and PON1) (GO:0070325). Proteins with lower 
abundances in the LT group included six isoforms of the SERPINA3 protein 
(SERPINA3–1, −2, −5, −6, −7 and − 8), ITIH4 and FN1. All eight proteins are 
involved in the GO peptidase regulator activity (GO:0061134) molecular function and 
all, with the exception of FN1 are also related to serine-type endopeptidase inhibitor 
activity (GO:0004867). Complete GO analysis is shown in Supplementary material 
(Table S8). 
For validation of proteomic results, plasma PON1 was determined and found 
increased with a statistical tendency (p = .06) in LT (125.55 U/L ± 9.70) compared to 
Ctrl (88.16 U/L ± 11.58). 
Table 1. Concentration of serum analytes and plasma AA which were found significantly 
different between Ctrl and LT groups (see Table S4 for complete results). 
Analyte Ctrl LT p-value 
Serum clinical chemistry 
Cholesterol (mg/dL) 60.29 ± 4.8 84.56 ± 9.48 0.041 
Glutathione Peroxidase (GPx) (U/L) 423.84 ± 38.22 321.89 ± 16.71 0.031 
Triglyceride (mg/dL) 19.69 ± 3.26 40.26 ± 11.21 0.058 
Analyte Ctrl LT p-value 
Plasma AA (μM) 
Histidine 71.45 ± 4.53 92.29 ± 9.06 0.048 
Isoleucine 94.72 ± 3.52 127.28 ± 13.37 0.017 
Leucine 164.74 ± 10.36 220.37 ± 28.84 0.056 
Table 2. Proteins with significantly differential abundances in skeletal muscle identified in 
Ctrl and LT groups. 
Gene name (Bos taurus) Protein description p-value fold change (LT vs Ctrl) 
HADHA 
Trifunctional enzyme subunit alpha, 
mitochondrial 
0.037 0.37 
PRDX1 Peroxiredoxin-1 0.030 0.26 
SOD2 Superoxide dismutase 2, mitochondrial 0.043 0.26 
SLC25A4 ADP/ATP-carrier protein 0.041 0.21 
VCP Transitional endoplasmic reticulum ATPase 0.041 0.20 
COX2 Cytochrome c oxidase 0.030 0.19 
COX5A Cytochrome c oxidase, subunit 5A, mitochondrial 0.030 0.19 
NDUFAB1 Chain U, Acyl Carrier Protein, mitochondrial 0.041 0.19 
ACO2 Aconitase 2, mitochondrial 0.071 0.11 
GYS1 Glycogen synthase 1 protein 0.025 −0.29 
RTN2 Reticulon-2 0.010 −0.25 
Table 3. Proteins with significantly differential abundances in plasma identified in Ctrl 
and LT groups. 
Gene name (Bos taurus) Protein description p-Value fold change (LT vs Ctrl) 
PON1 Paraoxonase 1 0.004 0.41 
APOA2 apolipoprotein A-II 0.009 0.35 
CRP C-reactive protein 0.025 0.35 
APOC3 Apolipoprotein C-III 0.015 0.33 
F2 Prothrombin 0.041 0.20 
SERPINA3–5 Serpin A3–5 0.018 −0.44 
SERPINA3–6 Serpin A3–6 0.018 −0.44 
ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 0.015 −0.34 
SERPINA3–8 Serpin A3–8 0.006 −0.31 
FN1 Fibronectin 0.034 −0.24 
Gene name (Bos taurus) Protein description p-Value fold change (LT vs Ctrl) 
SERPINA3–7 Serpin A3–7 0.041 −0.20 
SERPINA3–2 Serpin A3–2 0.013 −0.19 
SERPINA3–1 Serpin A3–1 0.018 −0.19 
3.4. Phosphorylation status of S6 in skeletal muscle 
The ratio of Phospho-S6/S6 in muscle was significantly increased in LT compared 
with Ctrl calves, as shown in Fig. 1. 
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Fig. 1. a. Western blot of Phospho-S6 and S6 with their corresponding total protein 
staining in each animal; b. Boxplots of S6, Phospho-S6 and the ratio of Phospho-S6/S6 
with comparison p-values between Ctrl and LT. Mean intensities were normalized and 
scaled to 1. 
3.5. Metabolomics in skeletal muscle and serum 
Quantified metabolites of muscle and serum with significant differences are shown 
in Table 4, Table 5, respectively. 
Table 4. Metabolites (mean ± SE, μMol/100 g muscle) with significantly differential 
concentration in skeletal muscle identified in Ctrl and LT groups. 
Metabolite Ctrl LT p-Value 
2-Oxoglutarate 0.80 ± 0.07 1.22 ± 0.10 0.005 
Acetate 1.08 ± 0.12 1.45 ± 0.13 0.052 
Acetoacetate 0.52 ± 0.04 0.67 ± 0.05 0.035 
GTP 0.50 ± 0.03 0.62 ± 0.02 0.005 
Leucine 0.51 ± 0.05 0.70 ± 0.07 0.042 
NADH 0.21 ± 0.04 0.35 ± 0.05 0.049 
Valine 0.94 ± 0.06 1.30 ± 0.11 0.013 
Table 5. Metabolites (mean ± SE, μM) with significantly differential concentration in 
serum identified in Ctrl and LT groups. 
Metabolite Ctrl LT p-Value 
2-Oxobutyrate 6.93 ± 0.71 10.00 ± 1.15 0.042 
2-Oxoisocaproate 4.09 ± 0.26 5.66 ± 0.30 0.002 
3-Hydroxybutyrate 44.73 ± 4.11 71.01 ± 9.57 0.021 
3-Hydroxyisobutyrate 9.34 ± 0.79 11.69 ± 0.57 0.034 
Asparagine 25.24 ± 1.42 30.17 ± 1.37 0.028 
Creatinine 15.86 ± 1.40 19.57 ± 1.15 0.064 
Formate 35.59 ± 2.37 30.60 ± 1.46 0.08 
Fructose 119.11 ± 10.24 83.50 ± 11.51 0.039 
Histidine 10.87 ± 1.21 16.70 ± 1.88 0.023 
Isoleucine 39.70 ± 2.24 50.31 ± 3.32 0.021 
Leucine 64.06 ± 3.96 81.19 ± 6.02 0.035 
Proline 53.79 ± 1.60 64.51 ± 2.40 0.002 
Metabolite Ctrl LT p-Value 
Serine 51.36 ± 2.40 68.80 ± 4.81 0.007 
Threonine 66.43 ± 5.00 78.94 ± 3.60 0.065 
Valine 59.11 ± 3.58 77.06 ± 6.35 0.03 
Carnitine 5.76 ± 0.25 8.10 ± 0.48 0.001 
Citrulline 39.16 ± 3.10 49.77 ± 1.39 0.009 
Methylsuccinate 4.46 ± 0.40 5.51 ± 0.32 0.061 
In muscle, two BCAA (leucine and valine), two citrate cycle-related metabolites (2-
oxoglutarate and GTP) as well as NADH and acetoacetate were significantly 
increased in LT animals. Furthermore, acetate showed a tendency for increase. 
In serum, seven proteinogenic AA (asparagine, histidine, isoleucine, leucine, proline, 
serine and valine) and one AA derivative (citrulline) were significantly increased in 
LT animals. Threonine showed a tendency to increase. Furthermore, catalytic 
metabolites derived from leucine (2-oxoisocaproate), threonine (2-oxobutyrate) and 
valine (3-hydroxyisobutyrate) as well as carnitine and 3-hydroxybutyrate, two 
metabolites related to lipid degradation, were also elevated. 
The PCA for the quantified metabolites with their corresponding loadings are shown 
in Fig. 2 for muscle (a) and serum (b), respectively. Verification of consistency with 
the original data was performed by matching PCA of chemometrics from both 
biological samples (Supplementary material Fig. S1). 
Correlation plots for all metabolites and proteins in muscle and serum are shown 
in Fig. 3a and b, respectively (p < .05). In muscle, leucine showed significant 
correlation with acetoacetate, carnitine as well as the other BCAA (isoleucine and 
valine). Also a positive correlation appeared between the proteins related to 
mitochondria and OXPHOS (COX2, COX5A, VCP and NDUFAB1), and between 
leucine and HADHA. In serum, the correlation plot revealed several positive 
correlations between leucine and/or threonine and several AA. SerpinA3.1, 
SerpinA3.7, PON1, CRP and APOC3 also clustered together showing a positive 
correlation, as well as SerpinA3.5, SerpinA3.6, SerpinA3.8, ITIH4 and APOA2. 
These two groups of proteins correlated negatively one to the other. 
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Fig. 2. Principal component analyses (PCA) with loadings of quantified metabolites from 
muscle (a) and serum (b). 
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Fig. 3. Correlation plots of quantified metabolites in muscle (a) and serum (b). Dark blue 
and dark red colors indicate stronger positive and negative correlation, respectively. 
Pearson r coefficients were calculated and significant level was set at p < .05. The larger 
size of the circle represents a high correlation coefficient (approaching to 1) whereas 
smaller size of the circle indicate the opposite (approaching to 0). Non-significant 
correlations are depicted with a cross on top of the circle. Compounds are grouped by 
hierarchical clustering order. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
The analysis of the correlation between metabolites in serum and muscle 
(Supplementary material Fig. S2) showed that muscular leucine and valine positively 
correlated with muscular and serum carnitine, and with serum citrulline and amino 
acids as isoleucine and lysine. Muscular NADP also correlated with several serum AA 
(isoleucine, leucine, lysine, proline, tryptophan, valine, phenylalanine). Negative 
correlations were observed between serum acetate and muscular glucose, glucose-1P 
and pyruvate; 2-oxobutyrate showed negative correlations with glucose, glucose-1P, 
glucose-6P and lactate; and serum lactate negatively correlated with muscular acetate. 
3.6. Pathway analysis 
The Reactome pathway for protein analysis yielded several significant pathways, in 
accordance with the GO ontology. The Reactome analysis for small molecules 
(KEGG nomenclature) also presented coherent results (Supplementary material Table 
S9). 
In muscle, citrate cycle and respiratory electron transport, mitochondrial fatty acid 
beta-oxidation and detoxification of reactive oxygen species were identified with 
proteomic data. Among the most relevant for metabolites, BCAA catabolism (R-HSA-
70895), metabolism of amino acids and derivatives (R-HSA-71291), synthesis of 
ketone bodies (R-HSA-77111), tRNA modification in the nucleus and cytosol (R-
HSA-6782315) and citrate cycle (R-HSA-71403) were observed. 
In plasma/serum, chylomicron assembly and remodeling (R-HSA-8963888 and R-
HSA-8963901) and lipoprotein assembly and remodeling (R-HSA-8963898 and R-
HSA-8963899) were identified with proteomic data and tRNA aminoacylation (R-
HSA-379724) and metabolism of AA and derivatives (R-HSA-71291) with small 
compounds. 
The joint pathway analysis of increased abundance proteins and metabolites in blood 
and muscle developed with MetaboAnalyst are shown in Table 6. Four pathways 
(valine, leucine and isoleucine degradation; butanoate metabolism, aminoacyl-tRNA 
metabolism; and citrate cycle) were found with significant change, furthermore 
coherent with the Reactome analysis. 
Table 6. Joint pathway analyses of upregulated proteins and metabolites in muscle and 
blood using MetaboAnalyst. 
Pathway Muscle (9 proteins and 9 metabolites) Blood (5 proteins and 16 metabolites) 

























































2/50 0.039 3.2 1 0.62 0.3 – – –  
p-value, p-values of significant pathways in enrichment analysis; Impact, impact of the pathway according to 
the pathway topology analysis. Higher -log(p) means more significant pathway; higher impact means a higher 
percentage of hit compounds. 
4. Discussion 
Schematics of the putative metabolic effects caused by leucine/threonine 
supplementation is shown in Fig. 4. Detailed explanation is given below. 
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Fig. 4. Schematic representation of the putative metabolic effects exerted by 
leucine/threonine supplementation in the MR in pre-weaned calves. 
4.1. Supplementation with leucine and threonine increases the concentration of 
BCAA and their derivative metabolites 
Metabolomic analysis indicated increases in the three BCAA in serum and muscle, 
which implies that leucine reached the blood and the muscle, and that a metabolic 
connection among BCAA exists. On the other hand, no increase in threonine neither 
in blood nor muscle was observed, despite being supplemented at the same level as 
leucine. Serine was greatly increased, thus this may be explained by the rapid 
conversion of threonine to serine. 
Most AA are first metabolized in the liver and turned into ketoacids by 
transamination. In contrast, BCAA are not initially metabolized in the liver, due to 
low hepatic activity of branched-chain-amino-acid aminotransferase (BCAT). Thus, 
BCAA increase rapidly in the plasma after protein intake and are readily available to 
extrahepatic tissues [28]. Most of the BCAA are initially catabolized in the skeletal 
muscle, due to its high BCAT activity, which can reversibly transfer the alpha-amino 
group in BCAA to 2-oxoglutarate (α-KG) to form glutamate and the corresponding 
branched-chain keto acids (BCKA): 2-oxo-isocaproate (ketoleucine), 2-oxo-3-
methylvalerate (ketoisoleucine) and 2-oxo-isovalerate (ketovaline). Glutamate can 
further form alanine or glutamine to be released in the bloodstream whereas BCKA 
are catabolized mainly in the liver [29]. Since the three BCAA have parallel pathways 
for degradation, the finding of higher concentrations of 2-oxoisocaproate and 3-
hydroxyisobutyrate in serum in the LT group indicates that these AA are indeed 
catabolized [30]. These AA and their metabolites (α-ketoisocaproic acid and β-
hydroxy-β-methylbutyrate) have been reported to play important roles in enhancing 
muscle growth during the neonatal period [31]. Positive correlation between muscular 
leucine, isoleucine and valine with serum citrulline and aspartate, both intermediates 
of the urea cycle, may indicate a higher degradation of amino acids as a general event 
of the organism, in the last stage of metabolism of the amino group in the urea cycle 
taking place in the liver. 
4.2. Supplementation with leucine and threonine affects lipid metabolism 
Results from the proteomic analysis indicated an increase in plasma apolipoproteins 
APOA2 and APOC3, which are involved in lipid and cholesterol transport 
(GO:2000910 and GO:0060621) in the LT group. Furthermore, PON1, an enzyme that 
is involved in detoxification, is bound to high-density lipoproteins (HDL) in plasma 
[32]. The increase in plasma apolipoproteins is consistent with the increase in TGs 
and cholesterol observed after conventional clinical chemistry assays. Regarding the 
increase in serum 3-hydroxybutyrate, it could likely be consequence of an increase in 
the production of butyrate in the rumen, since these young animals have already a 
partially functional rumen at the end of the experiment. 
4.3. Supplementation with leucine and threonine affects energy metabolism in 
skeletal muscle 
The proteomic and metabolomic data obtained from skeletal muscle biopsies 
highlighted other two main metabolic adaptations. On one hand, the pathway analysis 
showed an increase in oxidative metabolism as components of NADH dehydrogenase 
(Complex I) (NADH and NDUFAB1) and cytochrome c oxidase (Complex IV) 
(COX2 and COX5A) [33] were increased in the LT group, indicating an increase in 
the activity of the mitochondrial respiratory chain and oxidative phosphorylation 
(OXPHOS). OXPHOS would be fueled by a higher rate of the citrate cycle, as 
suggested by an upregulation of enzymes (ACO2) and metabolites (2-oxoglutarate, 
GTP and NADH). The ADP/ATP carrier protein SLC25A4, involved in the exchange 
of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner 
membrane, was also found at higher abundance. It is interesting to note that these 
proteins (COX2, COX5A and NDUFAB1, as well as VCP) clustered positively in the 
correlation analysis in muscle (Fig. 3A). The citrate cycle would be more active due to 
the fuel provided by BCAA, however it has been shown that it could also be fueled by 
an increase in fatty acid degradation, as carnitine, involved in the transport of fatty 
acids to the mitochondria, and HADHA, involved in fatty acid beta-oxidation, had 
both higher abundances in the LT group. Positive correlation between muscle leucine 
with carnitine in muscle and serum, and with HADHA in muscle, may also be an 
indicative of this metabolic adaptation. The metabolites acetoacetate and 3-
hydroxybutyrate also indicated an increase in the metabolism of Acetyl CoA. 
Nutrients (BCAA, butyrate and fats) are metabolized to acetyl-CoA, which 
subsequently enters the citrate cycle to finally produce ATP as energy for cellular 
processes [34]. Consequently, increased ATP availability leads to increased ATP 
transfer from mitochondria (upregulation of SLC25A4) as well as transport across 
membranes in other organelles (upregulation of the ATPase VCP). 
On the other hand, the increased abundance of PRDX1 and SOD2 in the muscle tissue 
pointed towards the activation of superoxide radicals removal (GO:0019430) [35]. 
Since OXPHOS is not completely efficient and not every oxygen receives four 
electrons, a greater amount of superoxide anions and peroxides are likely produced 
under OXPHOS activation. The increase in antioxidant defenses may be a 
compensatory mechanism for the increase in oxygen radicals. 
Another potential effect of leucine is its ability to increase protein synthesis through 
its effect on the mTOR complex 1 (mTORC1) which is known for its central 
regulation of cell metabolism, growth, proliferation, and survival [36]. There is 
evidence that leucine [37] as well as its metabolite 2-oxoisocaproate are able to 
activate mTOR [31,38]. Herein, we use the phosphorylation of the ribosomal protein 
S6, downstream of the mTORC1 signaling pathway, as an indicator of the mTORC1 
function, directly related to the upregulation of protein synthesis [39]. In our case, the 
ratio of phospho-S6/S6 indicated a significant upregulation of mTORC1 in the LT 
group. Our results suggest that the supplemented leucine stimulated the mTORC1 
pathway and protein synthesis, which may have contributed to the slight but 
significant increase in the protein percentage observed in LT calves after CT-imaging 
performed at the same time than biopsies (manuscript in preparation). 
Our present hypothesis is that supplementation with Leu-Thr would positively affect 
skeletal muscle growth (increase of muscular mass) by affecting two mechanisms: on 
one side, improving ribosomal protein synthesis through the phosphorylation of S6 
(putatively via mTOR) and, on the other side, by providing enough energy (ATP) to 
drive protein synthesis, which is energy-consuming. 
4.4. Supplementation with leucine and threonine affects plasma composition 
The metabolic effects were also visualized in plasma, due to the appearance of two 
oxidation/citrate cycle components (carnitine and 2-oxoglutarate), ketone bodies (3-
hydroxybutyrate and acetoacetate) and, as mentioned above, BCAA derivatives (2-
oxoisocaproate and 3-hydroxyisobutyrate). 
Changes in the plasma proteome indicated that leucine/threonine supplementation 
may have complex effects in the defense mechanisms of the organism (oxidative 
stress and native immune system): haptoglobin was not altered (Table S4), CRP and 
PON1 increased, ITIH4 decreased. PON1 is involved in detoxification and binds to 
HDL, preventing and delaying the oxidation of HDL and low-density lipoprotein 
(LDL) and therefore inhibiting the onset and progression of oxidative stress [40], 
whereas CRP and ITIH4 are acute phase proteins upregulated in acute phase response 
[41], although CRP is considered a minor acute phase protein in bovine [42]. On the 
other hand, a decrease in several serpin 3A isoforms was observed. Serpin A3 belongs 
to the serpin superfamily of protease inhibitors and it is encoded by a cluster of eight 
closely related genes in cattle [43]. The functionality of serpins remains unclear, but 
they may be involved in blood coagulation, fibrinolysis, cell migration, and hormone 
transport [44,45]. A hint on the potential physiological roles of different serpins may 
be inferred from the correlation analysis, since some serpins (A3.1, A3.7) positively 
correlated with PON1, CRP and APOC3, whereas other serpins (A3.5, A3.6 and 
A3.8) clustered together with ITIH4 and APOA2. Curiously, these two groups of 
proteins correlated negatively one to the other. In any case, further research is needed 
to clarify whether these processes can be affected by leucine supplementation and/or a 
metabolically tensed status exist in these animals. 
5. Conclusions 
Supplementation with leucine and threonine increased oxidative metabolism in 
muscle through an increase in citrate cycle, the mitochondrial respiratory chain and 
OXPHOS. The energy substrates were the AA, which were catabolized to ketoacids 
mainly in the muscle and may yield acetyl-CoA to enter the citrate cycle. Other 
substrates were short fatty acids and/or products of lipid mobilization, which were 
also converted into acetyl-CoA to be oxidized. The generation of oxidative stress in 
the mitochondria was balanced by the upregulation of antioxidant proteins. Lastly, a 
complex readjustment of the plasma defense systems also occurred. 
In conclusion, an integrative approach by combining metabolomics, proteomics and 
clinical chemistry allowed to characterize metabolic adaptations occurring in these 
animals, even in the absence of macroscopic changes in productive parameters. More 
studies to analyze the role of the rumen, adipose tissue and liver, and the metabolomic 
study of hydrophobic compounds would extend our understanding about the 
metabolism in dairy calves and may help to optimize their nutritional management. 
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Fig. S1. Principal component analyses (PCA) of muscle (a) and serum (b) chemometrics 
data. 
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Fig. S2. Correlation plots of quantified metabolites in muscle versus serum. Dark blue 
and dark red colors indicate stronger positive and negative correlation, respectively. 
Pearson r coefficients were calculated and significant level was set at p < .05. The larger 
size of the circle represents a high correlation coefficient (approaching to 1) whereas 
smaller size of the circle indicate the opposite (approaching to 0). Non-significant 
correlations are depicted with a cross on top of the circle. 
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